patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_730336 | REC_0016101 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 14.6 | 65 | female | 0 | 14 | 4 | 6 | alectinib 600 mg BID | 5.5 | true | MSI-H | 2026-03-15T05:36:01.602309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770011 | REC_0016102 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.9 | 67 | male | 1 | 9 | 4.9 | 5 | alectinib 600 mg BID | 7.8 | false | MSS | 2026-03-15T05:36:01.602701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514452 | REC_0016103 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 8.3 | 68 | female | 0 | 0 | 5.7 | 5 | sotorasib 960 mg daily | 14.9 | false | MSS | 2026-03-15T05:36:01.603105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522079 | REC_0016104 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 18.3 | 53 | female | 0 | 23 | 4.2 | 7 | osimertinib 80 mg daily | 6.4 | true | MSS | 2026-03-15T05:36:01.603486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248333 | REC_0016105 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 12.8 | 69 | male | 1 | 19 | 4.3 | 6 | osimertinib 80 mg daily | 17.7 | false | MSI-H | 2026-03-15T05:36:01.603857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598220 | REC_0016106 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 7.6 | 64 | female | 1 | 16 | 4.3 | 6 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:01.605119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234106 | REC_0016107 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.5 | 70 | female | 1 | 24 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:36:01.605637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490881 | REC_0016108 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 13.5 | 71 | male | 0 | 12 | 6.7 | 7 | alectinib 600 mg BID | 14.3 | false | MSI-H | 2026-03-15T05:36:01.606284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368523 | REC_0016109 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 10.3 | 68 | female | 1 | 15 | 7.3 | 1 | osimertinib 80 mg daily | 18.1 | false | MSS | 2026-03-15T05:36:01.606744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503930 | REC_0016110 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 18.5 | 74 | female | 2 | 25 | 4.8 | 2 | osimertinib 80 mg daily | 19.9 | true | MSS | 2026-03-15T05:36:01.607131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756612 | REC_0016111 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 15.3 | 65 | female | 0 | 17 | 5.1 | 1 | osimertinib 80 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:36:01.607513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123401 | REC_0016112 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.3 | 65 | female | 1 | 31 | 5.1 | 6 | pembrolizumab 200 mg q3w | 8.6 | false | MSS | 2026-03-15T05:36:01.607889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696009 | REC_0016113 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.4 | 78 | male | 2 | 44 | 6.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.6 | false | MSS | 2026-03-15T05:36:01.608354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455882 | REC_0016114 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 8.3 | 57 | male | 1 | 15 | 4.8 | 1 | osimertinib 80 mg daily | 22.9 | false | MSS | 2026-03-15T05:36:01.608781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782331 | REC_0016115 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.8 | 74 | male | 3 | 38 | 5.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 11.7 | false | MSS | 2026-03-15T05:36:01.609201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776946 | REC_0016116 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 20.1 | 74 | female | 2 | 2 | 5.4 | 7 | sotorasib 960 mg daily | 7.5 | true | MSI-H | 2026-03-15T05:36:01.609624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433948 | REC_0016117 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 16.1 | 68 | female | 1 | 14 | 7.4 | 6 | sotorasib 960 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:36:01.610048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458338 | REC_0016118 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 6.5 | 81 | female | 0 | 15 | 3.9 | 2 | sotorasib 960 mg daily | 16.5 | false | MSS | 2026-03-15T05:36:01.610450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213117 | REC_0016119 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 10.2 | 66 | female | 0 | 23 | 5.3 | 5 | alectinib 600 mg BID | 14.9 | true | MSI-H | 2026-03-15T05:36:01.610863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649530 | REC_0016120 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 10.8 | 49 | female | 0 | 13 | 6.7 | 6 | entrectinib 600 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:36:01.611230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486761 | REC_0016121 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.1 | 56 | female | 1 | 42 | 6.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.4 | false | MSS | 2026-03-15T05:36:01.611792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723721 | REC_0016122 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 9 | 72 | female | 1 | 12 | 5.9 | 6 | entrectinib 600 mg daily | 11.3 | true | MSS | 2026-03-15T05:36:01.612308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602440 | REC_0016123 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5 | 78 | female | 3 | 51 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:36:01.612725+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573038 | REC_0016124 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 8 | 68 | female | 1 | 14 | 5.1 | 7 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:36:01.613122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267969 | REC_0016125 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 6.5 | 59 | female | 1 | 20 | 5.5 | 7 | entrectinib 600 mg daily | 7.4 | true | MSS | 2026-03-15T05:36:01.613531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976617 | REC_0016126 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 11.2 | 76 | female | 1 | 16 | 6.1 | 4 | osimertinib 80 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:36:01.613905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617252 | REC_0016127 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 30 | 16.1 | 81 | male | 2 | 19 | 5.7 | 0 | sotorasib 960 mg daily | 46.9 | true | MSS | 2026-03-15T05:36:01.614302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862323 | REC_0016128 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.3 | 65 | female | 0 | 31 | 3.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 18.2 | false | MSS | 2026-03-15T05:36:01.614659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438609 | REC_0016129 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 23 | 5.8 | 78 | female | 2 | 31 | 4.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 40.5 | false | MSS | 2026-03-15T05:36:01.615213+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665627 | REC_0016130 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 23 | 11.8 | 57 | female | 1 | 6 | 6.8 | 0 | osimertinib 80 mg daily | 19.1 | true | MSI-H | 2026-03-15T05:36:01.615655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370186 | REC_0016131 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 15 | 66 | female | 1 | 23 | 7.4 | 2 | osimertinib 80 mg daily | 17.8 | false | MSI-H | 2026-03-15T05:36:01.616066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525227 | REC_0016132 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 9.8 | 61 | female | 1 | 21 | 6.5 | 2 | alectinib 600 mg BID | 22.2 | true | MSS | 2026-03-15T05:36:01.616520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805781 | REC_0016133 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 4.3 | 54 | male | 0 | 54 | 5.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.6 | false | MSS | 2026-03-15T05:36:01.616917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140984 | REC_0016134 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 14.4 | 71 | female | 2 | 10 | 5 | 2 | osimertinib 80 mg daily | 14.1 | false | MSS | 2026-03-15T05:36:01.617529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334269 | REC_0016135 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 14.2 | 53 | male | 0 | 21 | 5.7 | 2 | sotorasib 960 mg daily | 15.8 | true | MSI-H | 2026-03-15T05:36:01.617954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538580 | REC_0016136 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 9.2 | 62 | male | 1 | 15 | 6.8 | 1 | alectinib 600 mg BID | 22.5 | false | MSS | 2026-03-15T05:36:01.618316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169600 | REC_0016137 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10.2 | 63 | female | 0 | 7 | 3.7 | 1 | sotorasib 960 mg daily | 5 | false | MSS | 2026-03-15T05:36:01.618681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445394 | REC_0016138 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 13.5 | 77 | female | 2 | 20 | 5.2 | 2 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:36:01.619042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541691 | REC_0016139 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 4 | 80 | female | 2 | 26 | 5.9 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:36:01.619435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294263 | REC_0016140 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 11.1 | 79 | female | 2 | 14 | 4.9 | 0 | osimertinib 80 mg daily | 23.4 | true | MSS | 2026-03-15T05:36:01.619787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873396 | REC_0016141 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 5.8 | 76 | male | 0 | 51 | 6.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:01.620203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521051 | REC_0016142 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 13.7 | 74 | female | 2 | 13 | 5 | 7 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:36:01.620579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820466 | REC_0016143 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 7.3 | 54 | male | 0 | 11 | 5.8 | 6 | alectinib 600 mg BID | 13.3 | true | MSS | 2026-03-15T05:36:01.620958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975861 | REC_0016144 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 16.6 | 66 | female | 0 | 15 | 4.9 | 1 | osimertinib 80 mg daily | 25.8 | false | MSS | 2026-03-15T05:36:01.621489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859238 | REC_0016145 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 12.4 | 72 | female | 1 | 19 | 4.3 | 1 | sotorasib 960 mg daily | 28.9 | false | MSS | 2026-03-15T05:36:01.621901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587832 | REC_0016146 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 9.5 | 60 | female | 0 | 44 | 5.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:36:01.622294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434586 | REC_0016147 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 8.3 | 88 | female | 1 | 12 | 3.7 | 1 | sotorasib 960 mg daily | 34 | true | MSS | 2026-03-15T05:36:01.622903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838125 | REC_0016148 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.6 | 69 | female | 0 | 66 | 5.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:36:01.623348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926085 | REC_0016149 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 18.2 | 64 | female | 0 | 17 | 4.5 | 5 | pembrolizumab 200 mg q3w | 11.5 | false | MSI-H | 2026-03-15T05:36:01.623751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198294 | REC_0016150 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 9.7 | 64 | male | 1 | 10 | 5.7 | 5 | entrectinib 600 mg daily | 12 | false | MSS | 2026-03-15T05:36:01.624219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217596 | REC_0016151 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 11 | 78 | female | 2 | 12 | 4.5 | 6 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:36:01.624727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946091 | REC_0016152 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 12.2 | 80 | female | 2 | 10 | 5.1 | 6 | entrectinib 600 mg daily | 5.8 | false | MSS | 2026-03-15T05:36:01.625164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131758 | REC_0016153 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 14.9 | 79 | female | 1 | 14 | 5.8 | 1 | osimertinib 80 mg daily | 16.4 | false | MSS | 2026-03-15T05:36:01.625524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198356 | REC_0016154 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.9 | 53 | male | 0 | 61 | 3.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:36:01.625885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753918 | REC_0016155 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 4.3 | 63 | female | 0 | 14 | 4.3 | 6 | osimertinib 80 mg daily | 19.7 | true | MSS | 2026-03-15T05:36:01.626270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591347 | REC_0016156 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.7 | 73 | male | 1 | 5 | 5.5 | 4 | entrectinib 600 mg daily | 21.6 | true | MSI-H | 2026-03-15T05:36:01.626651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459616 | REC_0016157 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 3.7 | 50 | male | 0 | 24 | 6.5 | 8 | alectinib 600 mg BID | 8.9 | false | MSS | 2026-03-15T05:36:01.627010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122761 | REC_0016158 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 9.1 | 74 | female | 1 | 18 | 5.8 | 1 | osimertinib 80 mg daily | 8.1 | false | MSS | 2026-03-15T05:36:01.627383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376799 | REC_0016159 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 3.6 | 59 | female | 1 | 15 | 5.9 | 1 | pembrolizumab 200 mg q3w | 24.7 | false | MSS | 2026-03-15T05:36:01.627706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664047 | REC_0016160 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.5 | 77 | female | 2 | 31 | 5.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:36:01.628234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254216 | REC_0016161 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.3 | 58 | male | 0 | 10 | 5.9 | 5 | alectinib 600 mg BID | 13.6 | true | MSS | 2026-03-15T05:36:01.628648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475903 | REC_0016162 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 11.1 | 80 | female | 1 | 14 | 4.5 | 1 | osimertinib 80 mg daily | 26.1 | false | MSI-H | 2026-03-15T05:36:01.629022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781830 | REC_0016163 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.5 | 74 | male | 2 | 8 | 7 | 7 | alectinib 600 mg BID | 7.2 | true | MSS | 2026-03-15T05:36:01.629342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835151 | REC_0016164 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 3.1 | 80 | female | 0 | 27 | 5.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 29.9 | false | MSS | 2026-03-15T05:36:01.629646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494852 | REC_0016165 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 16.3 | 61 | male | 0 | 15 | 4.7 | 0 | osimertinib 80 mg daily | 39.2 | false | MSS | 2026-03-15T05:36:01.630044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919011 | REC_0016166 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 35 | 5.4 | 82 | male | 2 | 56 | 4.3 | 8 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:01.630560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246720 | REC_0016167 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 5.9 | 58 | female | 1 | 19 | 5.6 | 8 | entrectinib 600 mg daily | 9.7 | true | MSS | 2026-03-15T05:36:01.630929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189258 | REC_0016168 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.6 | 56 | female | 0 | 20 | 5.3 | 7 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:01.631227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179645 | REC_0016169 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.8 | 68 | female | 1 | 33 | 4.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.5 | true | MSS | 2026-03-15T05:36:01.631530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912297 | REC_0016170 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 12.7 | 70 | female | 2 | 18 | 6.7 | 6 | entrectinib 600 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:01.632040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819427 | REC_0016171 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 8.1 | 65 | male | 1 | 13 | 6.2 | 1 | entrectinib 600 mg daily | 18.1 | false | MSS | 2026-03-15T05:36:01.632519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979738 | REC_0016172 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 15.9 | 58 | female | 0 | 13 | 6.6 | 2 | sotorasib 960 mg daily | 24.6 | false | MSI-H | 2026-03-15T05:36:01.632886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641329 | REC_0016173 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.6 | 55 | male | 0 | 24 | 4.5 | 3 | sotorasib 960 mg daily | 12.3 | true | MSS | 2026-03-15T05:36:01.633386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140080 | REC_0016174 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 3.7 | 67 | female | 1 | 36 | 4.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.7 | false | MSS | 2026-03-15T05:36:01.633750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646447 | REC_0016175 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 9 | 73 | female | 1 | 9 | 4.9 | 6 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:36:01.634097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522407 | REC_0016176 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 16.9 | 66 | female | 1 | 18 | 4.8 | 3 | sotorasib 960 mg daily | 5.2 | false | MSI-H | 2026-03-15T05:36:01.634470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519495 | REC_0016177 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 11.8 | 61 | male | 0 | 24 | 7.3 | 7 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:36:01.634817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612626 | REC_0016178 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 15.9 | 70 | male | 2 | 16 | 4 | 2 | osimertinib 80 mg daily | 22.1 | false | MSS | 2026-03-15T05:36:01.635211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637351 | REC_0016179 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 8.8 | 76 | female | 2 | 45 | 5.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 5 | false | MSS | 2026-03-15T05:36:01.635625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983972 | REC_0016180 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 21 | 6.7 | 76 | female | 2 | 11 | 4.8 | 0 | sotorasib 960 mg daily | 13 | true | MSS | 2026-03-15T05:36:01.635987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266662 | REC_0016181 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 15.5 | 67 | female | 0 | 23 | 6.5 | 2 | alectinib 600 mg BID | 21.7 | false | MSI-H | 2026-03-15T05:36:01.636465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894560 | REC_0016182 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 5.7 | 68 | female | 0 | 23 | 6 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:36:01.636876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693077 | REC_0016183 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.2 | 65 | female | 0 | 8 | 6 | 4 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:36:01.637308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571458 | REC_0016184 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 14.6 | 74 | female | 1 | 14 | 5.6 | 7 | alectinib 600 mg BID | 14.9 | false | MSI-H | 2026-03-15T05:36:01.637719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983174 | REC_0016185 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 6.7 | 82 | female | 2 | 12 | 8.1 | 2 | alectinib 600 mg BID | 9.3 | true | MSS | 2026-03-15T05:36:01.638063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334167 | REC_0016186 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 10.8 | 83 | female | 2 | 22 | 6.4 | 4 | pembrolizumab 200 mg q3w | 14.8 | true | MSI-H | 2026-03-15T05:36:01.638607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_504938 | REC_0016187 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 15.1 | 75 | female | 1 | 9 | 6.4 | 1 | entrectinib 600 mg daily | 23.8 | false | MSI-H | 2026-03-15T05:36:01.639031+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810950 | REC_0016188 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.1 | 74 | female | 3 | 62 | 5 | 2 | pembrolizumab 200 mg q3w | 6 | false | MSS | 2026-03-15T05:36:01.639437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738698 | REC_0016189 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 7.1 | 69 | female | 0 | 67 | 6.9 | 2 | pembrolizumab 200 mg q3w | 30 | true | MSS | 2026-03-15T05:36:01.639828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150113 | REC_0016190 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 12.5 | 66 | male | 1 | 8 | 4 | 1 | sotorasib 960 mg daily | 20.1 | false | MSI-H | 2026-03-15T05:36:01.640274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797912 | REC_0016191 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11 | 59 | male | 0 | 12 | 4.1 | 1 | sotorasib 960 mg daily | 19 | false | MSI-H | 2026-03-15T05:36:01.640726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515222 | REC_0016192 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 3.8 | 61 | male | 0 | 50 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.5 | false | MSS | 2026-03-15T05:36:01.641163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727454 | REC_0016193 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 25 | 4.4 | 65 | female | 1 | 12 | 5.7 | 0 | pembrolizumab 200 mg q3w | 19.2 | true | MSS | 2026-03-15T05:36:01.641543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342882 | REC_0016194 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 9 | 63 | female | 0 | 51 | 4.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.7 | true | MSS | 2026-03-15T05:36:01.641906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858902 | REC_0016195 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 4.6 | 84 | female | 2 | 11 | 5.6 | 5 | entrectinib 600 mg daily | 16.3 | true | MSS | 2026-03-15T05:36:01.642261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431710 | REC_0016196 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.2 | 69 | female | 0 | 34 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 25.3 | false | MSS | 2026-03-15T05:36:01.642615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438910 | REC_0016197 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 5.3 | 56 | female | 0 | 25 | 3.2 | 7 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:36:01.642959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516069 | REC_0016198 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 12.4 | 66 | male | 1 | 20 | 5.5 | 1 | entrectinib 600 mg daily | 14.1 | true | MSS | 2026-03-15T05:36:01.643307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471747 | REC_0016199 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.3 | 76 | female | 2 | 16 | 4.4 | 2 | entrectinib 600 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:36:01.643819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505340 | REC_0016200 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.2 | 66 | female | 1 | 15 | 3 | 6 | sotorasib 960 mg daily | 13.2 | false | MSS | 2026-03-15T05:36:01.644240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.